SPECIAL ISSUE I YEARBOOK 2020

In association with

PHARMA ON

THE FRONTLINE

Up against a complex and evolving adversary, pharma led the fight to find a cure for Covid-19 in 2020

Repurposing drugs for Covid-19

What happens to whistleblowers?

Debunking puberty blocker myths

Repurposing drugs for Covid-19

What happens to whistleblowers?

Debunking puberty blocker myths

02/24/2024 11:00:00
  • Home | Pharma on the frontline
  • In this issue
  • Mimotopes
  • Contents
  • VEGA Australia
  • Biosynth Carbosynth
  • Ehlers-Danlos syndrome: The zebra in the room
  • Cytiva Company Insight
  • Cytiva
  • Turning pharma green: an eco-wish list for the industry
  • From Covid-19 to SARS: what becomes of the whistleblowers?
  • No time to waste: repurposing drugs to tackle covid-19
  • Intellectual property in the time of Covid-19
  • Recce Pharma: a new frontier in the fight against AMR
  • A century of cultures: celebrating the world’s oldest lab culture collection
  • Debunking myths about puberty blockers for transgender children
  • Crabby concoctions: why pharma’s thirst for crustacean blood is up for debate
  • From antitoxins to Covid-19 drugs: charting the history of antibody drugs
  • Events
  • Next issue
12/18/2020 00:00:00